Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 123.48B, Vertex Pharmaceuticals(VRTX) trades at $486.51. The stock has a price-to-earnings ratio of 29.43.
On 2026-07-10, Vertex Pharmaceuticals(VRTX) stock traded between a low of $484.33 and a high of $498.91. Shares are currently priced at $486.51, which is +0.5% above the low and -2.5% below the high.
Vertex Pharmaceuticals(VRTX) shares are trading with a volume of 293.57K, against a daily average of 2.55M.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $533.67 and a 52-week low of $362.50.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $533.67 and a 52-week low of $362.50.
VRTX News
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compa...
Key Points Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated into billion-dollar earnings. The biotech has ta...
Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Vertex Pharmaceuticals, retaining the price target of $575.00. Unlock powerful investing tools and...
Analyst ratings
79%
of 33 ratingsMore VRTX News
...
On Monday, Crinetics and Vertex entered into a definitive agreement under which Vertex will acquire Crinetics for $85 per share in cash, representing a total eq...
Key Points Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late Phase 3 clinical testing. 10 stocks we like be...
Key Points Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The deal adds a newly launched acromegaly drug and a l...
Jefferies downgraded Crinetics (CRNX) to Hold from Buy with a price target of $85, up from $55, after the company announced it will be acquired by Vertex Pharma...
Vertex expects to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing. Vertex’s...
Analyst Whitney Ijem from Canaccord Genuity maintained a Hold rating on Vertex Pharmaceuticals and keeping the price target at $436.00. Unlock powerful investi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.